Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups-Reference-Cited by-同舟云学术

Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups

Published:2022-05 Issue: Volume:247 Page:24-32
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Gencer Baris,Eisen Alon,Berger David,Nordio Francesco,Murphy Sabina A.,Grip Laura T.,Chen Cathy,Lanz Hans,Ruff Christian T.,Antman Elliott M,Braunwald Eugene,Giugliano Robert P

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference46 articles.

1. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS);Hindricks;Eur Heart J,2021

2. Edoxaban versus warfarin in patients with atrial fibrillation;Giugliano;N Engl J Med,2013

3. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)

4. The safety of NOACs in atrial fibrillation patient subgroups: a narrative review;Lip;Int J Clin Pract,2019

5. Individualizing treatment choices in the systolic blood pressure intervention trial;Ferreira;J Hypertens,2018

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation;JAMA Cardiology;2024-09-01

2. Direct Oral Anticoagulants in Older and Frail Patients with Atrial Fibrillation: A Decade of Experience;Drugs & Aging;2024-08-14

3. Enhancing the study on antithrombotic therapy after stroke in AF patients;Europace;2024-06

4. Differences in quality of anticoagulation care delivery according to ethnoracial group in the United States: A scoping review;Journal of Thrombosis and Thrombolysis;2024-05-11

5. Impact of the PATH Statement on Analysis and Reporting of Heterogeneity of Treatment Effect in Clinical Trials: A Scoping Review;2024-05-06